Table 2:

Results of monopolar review. Side-effect thresholds, therapeutic thresholds, pulse width (PW), frequency (FRQ). “SE region” indicates the brain region that was associated with the observed side effects, and “?” marks side effects that could not clearly be assigned to one region (see Section 2.3). “o” marks the contact used in the patient’s primary program, which was determined to provide the best therapeutic effect during the monopolar review. “x” marks the contact used in the patient’s alternative program.

Patient #			C0	C1	C2	C3	PW [μs]	FRQ [Hz]
P1R	Side effect	[V]	0.6	0.8	0.8	3.0	60	185
	SE region		Vc	Vc	Vc	Vc
	Therapeutic	[V]	-	-	-	2.5
	Clinically used					o
P1L	Side effect	[V]	0.5	1.0	1.6	1.8	60	185
	SE region		Vc	Vc	Vc	Vc
	Therapeutic	[V]	-	0.8	1.5	1.6
	Clinically used			x	o
P2L	Side effect	[V]	0.8	1.8	1.8	1.6	90	180
	SE region		Vc	Vc, ?	Vc	Vc
	Therapeutic	[V]	0.7	1.5	-	-
	Clinically used			o
P3R	Side effect	[V]	0.5	0.5	1.8	2.3	60	180
	SE region		Vc	Vc	Vc	Vc
	Therapeutic	[V]	-	-	1.5	1.6
	Clinically used				o	x
P3L	Side effect	[V]	0.7	2.8	3.4	4.0	60	180
	SE region		Vc	IC, Vc	IC, Vc	IC
	Therapeutic	[V]	-	2.0	3.0	3.8
	Clinically used			o	x